Zefamenib
Zefamenib (BN-104) is an effective selective brain membrane protein inhibitor with oral activity, and it's also a Menin inhibitor, it can block the Menin-MLL interaction and leads to the degradation of Menin protein. Zefamenib is a weak hERG inhibitor, with an IC50 greater than 100 μM. Zefamenib has anti-tumor activity and can be used in cancer research, such as for acute myeloid leukemia[1].
Product Specifications
CAS Number
2938995-50-5
Product Name Alternative
BN-104; BNM-1192; Menin-MLL inhibitor 27
UNSPSC
12352005
Target
Epigenetic Reader Domain; Potassium Channel
Type
Reference compound
Related Pathways
Epigenetics; Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bn-104.html
Purity
99.95
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C([C@@H]1[C@]2([H])[C@](CCC2)([H])CN1)N3CCC4(CC3)CN(C5=NC=NN=C5OC6=C(C7=CN=CN=C7C8CC8)C=C(C=C6)F)C4
Molecular Formula
C31H35FN8O2
Molecular Weight
570.66
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Cynomolgus B7-1/CD80 Protein (His Tag)
Recombinant Cynomolgus B7-1/CD80 Protein (His Tag)
ARF1 (Golgi Apparatus Marker) (1A9/5), CF647 conjugate, 0.1mg/mL
